- Home
- SCWO vs IPHA Comparison
SCWO vs IPHA Comparison
Compare SCWO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCWO | IPHA |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SCWO | IPHA |
|---|---|---|
| Price | $0.29 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.1M | 21.7K |
| Earning Date | 11-12-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,910,340.00 | ★ $14,839,695.00 |
| Revenue This Year | $5,945.19 | $22.29 |
| Revenue Next Year | $106.82 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 508.52 | N/A |
| 52 Week Low | $0.16 | $1.47 |
| 52 Week High | $1.09 | $3.51 |
Technical Indicators
Market Signals| Indicator | SCWO | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 42.81 |
| Support Level | $0.26 | $1.85 |
| Resistance Level | $0.29 | $1.91 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 47.40 | 11.63 |
Price Performance
Historical ComparisonAbout SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.